Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension

By O. Sitbon, M. Humbert, X. Jaïs, V. Ioos, A. Hamid, S. Provencher, G. Garcia, F. Parent, P. Hervé, G. Simonneau. Circulation, 2005

1,189 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Definitions and diagnosis of pulmonary hypertension. (2013, background): “Inhaled nitric oxide at 10 to 20 parts per million is the gold standard for pulmonary vasoreactivity testing (30); intravenous epoprostenol (2 to 12 ng/kg/min), intravenous adenosine (50 to 350 mg/min), and inhaled iloprost (5 mg) can be used as alternatives (31,32).”
Mechanisms of disease: pulmonary arterial hypertension (2011, background): “191 Ongoing work to understand the molecular basis of this response, by comparing genomic sequences from responders and nonresponders, might provide a noninvasive test to guide the prescription of calcium antagonists for patients with IPAH. Circulating protein biomarkers, such as B-type natriuretic ”
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. (2006, background): “…nitric oxide (NO), intravenous epoprostenol, or intravenous adenosine is recommended as part of the diagnostic workup of patients with pulmonary arterial hypertension (1,2,15) because patients who are acutely vasoreactive may beneﬁt from high-dose, long-term calcium channel blocker therapy (16).”
Pulmonary arterial hypertension (2013, background): “one year without the need for additional treatment [205].”